Flamingo Ai inks contract with Nationwide in first paid engagement for LIBBY

|

Published 14-DEC-2018 10:46 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

AI and machine learning tech junior, Flamingo Ai Limited (ASX:FGO), has signed a statement of work (SoW) with US Fortune 100 company, Nationwide Mutual Insurance, for the use of its machine learning-based analytics and ‘self-organising library’ product, LIBBY.

Nationwide will use LIBBY to analyse large and complex unstructured data-sets in one of its departments, and will also be assessing LIBBY’s suitability for use across its broader business as an unsupervised machine learning based analytics tool.

While the revenue associated with the contract is regarded by the ASX small cap as not material at this time, this deployment strengthens FGO's relationship with Nationwide, a client since 2015. Since May 2016, FGO has operated under a master services agreement (MSA) with Nationwide.

In 2017, FGO successfully completed Nationwide’s highly rigorous security and data privacy audits and technology architecture reviews, resulting in FGO also achieving SOC2 Type 1 Certification — an important selling point for current and future engagements.

This newly announced contract, meanwhile, represents FGO’s first paid engagement of LIBBY. The company noted that it has received strong interest in the product in the US and Asia Pacific from several existing and potential clients across insurance, banking and investment.

At the same time, the ASX junior reported that it has received a high level of interest in its MAGGIE virtual inquiry assistant product — a quick-to-market AI solution designed to solve problems related to the high level of inefficiency many organisations experience in organising, storing, and retrieving knowledge.

“We are pleased to have secured this additional contract with Nationwide, a client we have been working with since 2015. Their continued interest and take-up of our new AI product through this SoW is particularly encouraging and bodes well for future, and of course, material deployments. It is another very positive step with a large Fortune 100 company,” FGO CEO, Dr Catriona Wallace, said of today’s contract win.

“As well, we are witnessing growing interest in the MAGGIE AI solution and we look forward to reporting on progress with trials and deployments as they are locked in.

“There is very positive momentum in our business development pipeline and we are very focused and committed to converting these opportunities into longer-term, revenue generating contracts.”

Investors seem to concur. FGO is currently up 14% on the back of today's news.

Who or what is LIBBY?

LIBBY is one of FGO’s newest products, which it created and brought to market after conducting in-market testing with companies in the financial services and telecommunications sector.

The core capability is LIBBY’s automatic structuring of unstructured data, using IP that was built entirely in-house. This application solves a key business problem – the inefficiency of enterprises to manage, store, retrieve, analyse and gain insights from their vast quantities of unstructured, conversational and non-form data.

LIBBY can ingest, analyse and automatically structure large unstructured data sets; analyse large data sets and generate previously unknown insights related to customers’ experiences; self-organise information into new categories that provide new insights; identify areas of poor customer experience, product issues and process inefficiencies; and generate reports containing commercial insights.

In October, FGO announced a contract extension with major client, CUA Health Ltd (a subsidiary of Credit Union Australia), to extend its use of FGO’s Cognitive Virtual Sales Assistant, ‘Sam’.

Based on encouraging results from a trial, CUA Health signed the extension of contract, which was inclusive of a monthly subscription fee for the Virtual Sales Assistant for health insurance.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X